Ironwood Pharma (IRWD) Reports Q2 Loss Per Share of 34c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update
August 5, 2015 4:01 PM EDTLINZESS® (linaclotide) U.S. net sales of $112.1 million in second quarter 2015
Total LINZESS prescriptions increased approximately 56% in second quarter 2015 compared to second quarter 2014
Advanced innovative pipeline, including positive top-line Phase I data with sGC stimulator IW-1973
Entered agreement with Allergan to co-promote VIBERZI (eluxadoline) for IBS-D
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals,... More
